Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIb trial of EVT-201 for treatment of insomnia in China

Next Previous
Trial Profile

Phase IIb trial of EVT-201 for treatment of insomnia in China

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dimdazenil (Primary)
  • Indications Insomnia
  • Focus Therapeutic Use
  • Sponsors Zhejiang Jingxin Pharmaceutical

    • Most Recent Events

    • 14 Mar 2015 Status changed from not yet recruiting to recruiting in 2014, according to an Evotec media release.
    • 12 Aug 2014 According to an Evotec media release, JingXin Pharmaceutical Co., Ltd, received approval from the China State Food and Drug Administration (SFDA) for this study and plans to start in the second half of 2014.
    • 09 Aug 2013 According to an Evotec media release, Zhejiang JingXin Pharmaceutical was granted permission in April 2013 by the Chinese Center of Drug Evaluation (CDE) to commence clinical trials of EVT 201.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top